Truvada (emtricitabine / tenofovir disoproxil) vs Apretude (cabotegravir extended-release injectable suspension)
Truvada (emtricitabine / tenofovir disoproxil) vs Apretude (cabotegravir extended-release injectable suspension)
Truvada (emtricitabine/tenofovir disoproxil) is an oral medication taken daily for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in individuals at high risk, whereas Apretude (cabotegravir extended-release injectable suspension) is an injectable form of PrEP administered once every two months after an initial loading dose. Truvada has been widely used for PrEP since its approval and has a well-established safety profile, but it requires adherence to a daily regimen. In contrast, Apretude offers a less frequent dosing schedule, which may be more convenient for some individuals, but it is a newer medication, and patients must be comfortable with receiving injections from a healthcare provider.
Difference between Truvada and Apretude
Metric | Truvada (emtricitabine / tenofovir disoproxil) | Apretude (cabotegravir extended-release injectable suspension) |
---|---|---|
Generic name | Emtricitabine / Tenofovir disoproxil | Cabotegravir extended-release |
Indications | HIV-1 infection prevention in at-risk populations, treatment of HIV-1 in combination with other antiretroviral agents | HIV-1 infection prevention in at-risk populations |
Mechanism of action | Reverse transcriptase inhibitors | Integrase strand transfer inhibitor (INSTI) |
Brand names | Truvada | Apretude |
Administrative route | Oral | Injectable |
Side effects | Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash | Injection site reactions, fever, fatigue, headache, musculoskeletal pain, sleep disorders, rash |
Contraindications | Patients with known hypersensitivity to emtricitabine or tenofovir disoproxil fumarate | Patients with known hypersensitivity to cabotegravir |
Drug class | Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | Integrase Strand Transfer Inhibitor (INSTI) |
Manufacturer | Gilead Sciences | ViiV Healthcare |
Efficacy
Efficacy of Truvada for HIV Prevention
Truvada, a combination of emtricitabine and tenofovir disoproxil, has been widely recognized for its efficacy in the prevention of HIV/AIDS. As a form of pre-exposure prophylaxis (PrEP), Truvada is highly effective when taken consistently and correctly. Clinical trials have demonstrated that Truvada can reduce the risk of sexually acquired HIV infection by up to 92% among individuals at high risk who take the medication daily as prescribed. However, the level of protection decreases significantly when the medication is not taken consistently. For individuals who adhere to the recommended daily regimen, Truvada provides a substantial level of protection against HIV.
Truvada for Treatment of HIV/AIDS
While Truvada is well-known for its preventive capabilities, it is also used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients. In treatment settings, Truvada's efficacy is contingent upon its use as part of a regimen that suppresses HIV viral load. Patients on Truvada, as part of a comprehensive treatment plan, have shown significant reductions in viral load and improvements in CD4+ T-cell counts, which are crucial for a healthy immune system.
Efficacy of Apretude for HIV Prevention
Apretude (cabotegravir extended-release injectable suspension) represents a newer option for HIV prevention as a long-acting injectable form of PrEP. The efficacy of Apretude has been evaluated in several clinical trials, including the HPTN 083 and HPTN 084 studies. These studies have shown that Apretude is highly effective in reducing the risk of acquiring HIV. In HPTN 083, Apretude was found to be more effective than daily oral Truvada for PrEP among cisgender men and transgender women who have sex with men. HPTN 084 demonstrated similar results in cisgender women, showing that Apretude was superior to daily oral Truvada in preventing HIV infection.
Considerations for Apretude Usage
Apretude is administered as an intramuscular injection once every two months after an initial loading phase. This dosing schedule offers an alternative to daily oral medication, which can be a significant advantage for individuals who prefer less frequent dosing or have difficulty with adherence to daily pills. The long-acting nature of Apretude provides sustained levels of medication in the body, which is critical for maintaining its preventive efficacy. However, it is important to note that individuals must adhere to the injection schedule to maintain protection against HIV.
Regulatory Agency Approvals
Truvada
Apretude
Access Truvada or Apretude today
If Truvada or Apretude are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us